Pennsylvania Regulations: Communicable and Noncommunicable Diseases
Comment: Submitted to the Pennsylvania Department of Health
Population Health
Policy
Patient Focused Drug Development: Methodologic and Other Challenges Related to Patient Experience Data
Comment: Submitted to the Food and Drug Administration and Department of Health and Human Services
Print:
On December 18, 2024, LDI Senior Fellow Sean Hennessy, PharmD, PhD submitted a comment in response to a Request for Comments from the U.S Food and Drug Administration and U.S. Department of Health and Human Services. The request sought input regarding methodological challenges related to data on patient experience.
As an expert in pharmacoepidemiology, the study of the health effects of drugs and other medical products in populations, Dr. Hennessy provides 10 suggestions for improving the use of patient experience data in patient focused drug development.
Views expressed by the researchers are their own and do not necessarily represent those of the University of Pennsylvania Health System (Penn Medicine) or the University of Pennsylvania.
More on Policy at LDI
Establishing a Strong Quantitative Medicine Innovation Network
Comment: Submitted to the Food and Drug Administration
Comments on the Regulation of Federal Financial Assistance
Comment: Delivered to the Office of Management and Budget
The State of LGBTQ+ Health in Philadelphia
Testimony: Delivered to Philadelphia City Council’s Committee on Public Health and Human Services by Amy Hillier
The State of LGBTQ+ Health in Philadelphia
Testimony: Delivered to Philadelphia City Council’s Committee on Public Health and Human Services by Aaron Richterman
Rural Health Transformation in Pennsylvania: Rural Access and Care Delivery
Testimony: Delivered to the Center for Rural Pennsylvania Board of Directors Public Hearing